Lyell Immunopharma, Inc. (LYEL)
12.26
-0.62
(-4.81%)
USD |
NASDAQ |
Sep 10, 15:23
Lyell Immunopharma Total Liabilities (Quarterly) : 77.34M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 77.34M |
| March 31, 2026 | 76.96M |
| December 31, 2025 | 91.85M |
| September 30, 2025 | 78.84M |
| June 30, 2025 | 86.53M |
| March 31, 2025 | 93.28M |
| December 31, 2024 | 108.04M |
| September 30, 2024 | 88.52M |
| June 30, 2024 | 87.64M |
| March 31, 2024 | 91.06M |
| December 31, 2023 | 95.08M |
| September 30, 2023 | 97.42M |
| Date | Value |
|---|---|
| June 30, 2023 | 98.50M |
| March 31, 2023 | 96.62M |
| December 31, 2022 | 104.31M |
| September 30, 2022 | 157.24M |
| June 30, 2022 | 153.63M |
| March 31, 2022 | 190.85M |
| December 31, 2021 | 197.62M |
| September 30, 2021 | 211.86M |
| June 30, 2021 | 207.91M |
| March 31, 2021 | 1.211B |
| December 31, 2020 | 1.201B |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
| Anixa Biosciences, Inc. | 1.873M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 311.15M |
| Shareholders Equity (Quarterly) | 233.82M |
| Debt to Equity Ratio | 0.1993 |
| Current Ratio | 5.356 |
| Net Debt Paydown Yield | 0.64% |